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It has been reported that reactive oxygen species (ROS), such as hydrogen peroxide and superoxide,
take part in osteoclast differentiation as intra-cellular signaling molecules. The current assumed sig-
naling cascade from RANK to ROS production is RANK, TRAF6, Rac1, and then Nox. The target molecules
of ROS in RANKL signaling remain unclear; however, several reports support the theory that NF-κB
signaling could be the crucial downstream signaling molecule of RANKL-mediated ROS signaling.
Furthermore, ROS exert cytotoxic effects such as peroxidation of lipids and phospholipids and oxidative
damage to proteins and DNA. Therefore, cells have several protective mechanisms against oxidative
stressors that mainly induce cytoprotective enzymes and ROS scavenging. Three well-known me-
chanisms regulate cytoprotective enzymes including Nrf2-, FOXO-, and sirtuin-dependent mechanisms.
Several reports have indicated a crosslink between FOXO- and sirtuin-dependent regulatory me-
chanisms. The agonists against the regulatory mechanisms are reported to induce these cytoprotective
enzymes successfully. Some of them inhibit osteoclast differentiation and bone destruction via at-
tenuation of intracellular ROS signaling. In this review article, we discuss the above topics and sum-
marize the current information available on the relationship between cytoprotective enzymes and
osteoclastogenesis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Osteoclasts are multi-nucleated cells that resorb bone tissue [1]
and are differentiated from macrophage–monocyte cell lines [2].
Osteoclast differentiation, namely osteoclastogenesis, is strictly
regulated by receptor activator of nuclear factor kappa-B ligand
(RANKL), an osteoclastogenic signaling cytokine [3]. Reactive
oxygen species (ROS), such as hydrogen peroxide and superoxide,
work as intracellular signaling molecules following RANKL sig-
naling during osteoclastogenesis [4–6]. However, apart from their
role as intracellular signaling molecules, ROS exert cytotoxic ef-
fects such as peroxidation of lipids and phospholipids [7], and
oxidative damage to proteins and DNA [8]. Therefore, cells have
several protective mechanisms against these oxidative stressors
[9–11] most of which induce cytoprotective enzymes [12–20] and
ROS scavenging. Taken together, it is thought that cytoprotectiveB.V. This is an open access article
ntics, School of Dental Med-
nzaki).mechanisms are attenuated during osteoclastogenesis to intensify
intracellular ROS signaling.
In this review article, we have summarized the relationship
between osteoclastogenesis and the protective mechanisms that
work against oxidative stressors.2. ROS work as intracellular signaling molecules during
osteoclastogenesis
RANKL is an essential cytokine in osteoclastogenesis [1,21–23],
and various intracellular signaling molecules, such as nuclear
factor of activated T-cells (NFAT) [24], mitogen-activated protein
kinase (MAPK) [25,26], tumor necrosis factor receptor-associated
factor (TRAF) [27,28], c-jun N-terminal kinase (JNK) [29], Akt [30],
and ROS [4,5] have been identiﬁed. ROS are interesting molecules
because not only do they work as intracellular signaling molecules,
but also they increase with age or with the onset of an in-
ﬂammatory state, which subsequently leads to bone destruction
[31–37]. In addition, exogenous hydrogen peroxide induces os-
teoclastogenesis [38], signifying that oxidative stress participatesunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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toplasm and extracellularly.
It is reported that TRAF6 plays a key linkage role in ROS pro-
duction by RANKL [39]. We reported that dominant-interfering
mutant form of TRAF6, signiﬁcantly decreased ROS induction, al-
though TRAF6 itself does not directly produce ROS. Rac, a func-
tional downstream molecule and member of the Rho-GTPase
subfamily, which is involved in the organization of the cytoske-
leton, is a cytosolic component of NADPH oxidase (NOX) complex
and responsible for the activation of NOXs [40]. The expression of a
dominant-negative mutant of Rac1 blocks ROS production, sig-
nifying that Rac1 is responsible for regulating the generation of
ROS during osteoclast differentiation [41]. In addition, NOXs have
been reported as essential enzymes that produce ROS during os-
teoclast differentiation [42–44]. Taken together, the current as-
sumed signaling cascade from RANK to ROS production is RANK,
TRAF6, Rac1, and then NOX.
The target molecules of ROS in RANKL signaling remain un-
clear; however, several reports have suggested that MAPK, PI3K,
and NF-kB activation are downstream events [45,46]. Additionally,
Bharti et al. reported that curcumin, which has ROS-scavenging
properties, inhibits RANKL-induced NF-κB activation, which in-
dicates that NF-κB signaling could be the crucial downstream
signaling molecule of RANKL-mediated ROS signaling [47]. Current
information about the intracellular signaling cascade of RANKL is
summarized in Fig. 1.3. Defense mechanisms against ROS
As mentioned previously, ROS exhibit cytotoxicity [7,8];
therefore, cells have several protective mechanisms against these
oxidative stressors that mainly induce cytoprotective enzymes and
ROS scavenging. The mechanisms regulating cytoprotective en-
zymes are summarized in Table 1.
The most renowned regulator of cytoprotective enzymes is
transcriptional factor nuclear factor E2-related factor 2 (Nrf2),
which controls the gene expression of many cytoprotective en-
zymes, such as heme oxygenase-1 (HO-1) [13], NAD (P) H: quinone
reductase (NQO1) [14], gamma-glutamylcysteine synthetase (GCS)
[15], and the auxiliary cellular NADPH regenerating enzyme, glu-
cose 6-phosphate dehydrogenase (G6PD) [16] (Fig. 2); all of these
enzymes are ROS scavengers [17–20]. However, kelch-like ECH-
associated protein 1 (Keap1) negatively regulates Nrf2-dependent
transcription of cytoprotective enzymes by inhibiting nuclear
translocation, cytoplasmic ubiquitination, and degradation of Nrf2
[48].Fig. 1. Summary of the current information about the intracellular signaling cas-
cade of RANKL. Intracellular signaling molecules after RANK were identiﬁed. The
current assumed signaling cascade from RANK to ROS production is also described.
Some reports suggest that NF-κB is the crucial downstream molecule of RANKL-
mediated ROS signaling.FOXO ubiquitous transcription factors, which are depho-
sphorylated and subsequently activated by oxidative stress, are
involved in the regulation of redox balance [49–53]. It is reported
that oxidative stress activates FOXO via mammalian Ste20-like
kinases [50] and p66shc [51]. In addition, FOXO3 and 4 regulate
the expression of superoxide dismutase (SOD) [51,54] and catalase
(CAT) [55], and SOD converts superoxide to hydrogen peroxide
[56], which is subsequently detoxiﬁed by CAT (Fig. 3) [57]. Three
isozymes of SOD—SOD1, 2, and 3—have been identiﬁed and char-
acterized in mammals [58]. SOD1 is located in the cytoplasm,
SOD2 in the mitochondria, and SOD3 is extracellular. SOD1 and
SOD3 are Cu-Zn-SOD types, whereas SOD2 is Mn-SOD.
Sirtuin, which was originally identiﬁed as a protein deacetylase
[59], is also a regulator of the expression of cytoprotective en-
zymes such as SOD [60,61] and CAT (Fig. 4) [62]. Mammalian sir-
tuins consist of seven members (SIRT1–7), and have been im-
plicated in various cellular responses including aging, transcrip-
tion, apoptosis, and stress resistance [63]. Among them, the
functions of Sirt1 and 3 in oxidative stress responses have been
reported. SIRT1 deacetylates FOXO3 and 4 [53], which results in
the upregulation of Mn-SOD [64]. Furthermore, Olmos et al. re-
ported that SIRT1-dependent upregulation of cytoprotective en-
zymes depended on the formation of a FOXO3a/PGC-1α complex
in vascular endothelial cells [65]. However, Chen et al. reported
that SIRT3 directly upregulated SOD2 [60]. Regarding the cross-
linking between SIRT and Nrf2, Huang et al. reported that SIRT1
upregulated HO-1 and SOD1 via induction of Nrf2 [66]. Overall,
sirtuins, especially SIRT1 and 3, directly or indirectly regulate cy-
toprotective enzymes.4. Cytoprotective enzymes and osteoclastogenesis
Since ROS operate as intracellular signaling molecules during
osteoclastogenesis, a close relationship between osteoclastogen-
esis and cytoprotective enzymes is to be expected. Indeed, a well-
known cytoprotective enzyme, HO-1, is a negative regulator of
osteoclastogenesis [67–69]. Relationships between the mechan-
isms regulating cytoprotective enzymes and osteoclastogenesis
have also been reported. Rana et al. reported that loss of Nrf2
accelerates ionizing radiation-induced bone loss in Nrf2 knock-
out mice [70]. Other groups have reported that Nrf2 negatively
regulates osteoclastogenesis through attenuation of RANKL-
mediated intracellular ROS signaling by cytoprotective enzymes
[71,72]. Furthermore, we previously reported that overexpression
of Nrf2 induces the expression of cytoprotective enzymes,
attenuates intracellular ROS signaling, and thereby inhibits
osteoclastogenesis [71]. Both overexpression of Nrf2 and Nrf2
activation (induction of nuclear translocation) inhibit osteoclas-
togenesis [6,73,74]. These lines of evidence suggest that Nrf2
activation could be a therapeutic approach towards bone de-
structive diseases such as rheumatoid arthritis, osteoporosis, and
periodontitis.
Another mechanism regulating cytoprotective enzyme FOXO
contributes to the control of osteoclastogenesis. Bartell et al. re-
ported that FOXO protein attenuates osteoclastogenesis via aug-
mentation of cytoprotective enzymes [75]. Sirtuins, originally
identiﬁed as protein deacetylases, have been reported as sup-
pressors of osteoclastogenesis. SIRT1 suppresses osteoclastogen-
esis by the upregulation of cytoprotective enzymes via FOXO-
mediated transcription and subsequent attenuation of intracellular
ROS signaling [76]. Lee et al. reported that the overexpression of
SIRT6, an NAD (þ)-dependent deacetylase, suppresses bone de-
struction in a collagen-induced arthritis mouse model [77]. These
lines of evidence suggest that the key molecule among the me-
chanisms regulating cytoprotective enzymes (Nrf2, FOXO, and
Table 1
Regulatory mechanisms of cytoprotective enzymes.
Regulator Cell type/experimental model Tested function/ﬁndings References
Nrf2 L929 ﬁbroblast, mutant Nrf2 expression Mutant Nrf2 decreased HO-1 [13]
Rat NQO-1 gene, promoter assay Nrf2 regulated NQO-1 [14]
Human GCS gene, promoter assay Nrf2 regulated GCS [15]
Nrf2 knockout mice Nrf2 KO decreased NQO-1 and GCS [16]
FOXO Breast cancer cells FOXO3 regulates MnSOD [49]
Primary mammalian neurons MST-FOXO axis controls oxidative-stress response [50]
C. elegans and mice gene pp66shc controls oxidative-stress response via FOXO3 (FKHRL1) [51]
Mutant mice Insulin/IGF-1-FOXO pathway relates oxidative-stress Response [52]
Mammalian cells Mammalian SIRT1 deacetylates FOXO3 and/or FOXO4 [53]
Mammalian cells FOXO3 directly increase MnSOD [54]
Mouse NIH3T3 cells ROS-Ral-JNK axis mediates FOXO4-dependent MnSOD upregulation [55]
SIRT
Human HEK293 cells SIRT3 deacetylates and activates MnSOD [60]
Mammalian cells SIRT3 activates MnSOD [61]
Renal tubular cells SIRT1 activates catalase via FOXO3 [62]
Mammalian cells SIRT1 activates MnSOD via FOXO4 [64]
Fig. 2. Nrf2-mediated cytoprotective enzymes scavenge ROS. Nrf2 transcriptionally
regulates the expressions of HO1, GCS, NQO1, and G6PD. HO1 convert heme into
carbon oxide (CO) and bilirubin, and they scavenge ROS. GCS increases intracellular
glutathione, which results in ROS scavenging. NQO1 reduces oxyradicals. G6PD
increases intracellular NADPH, which augments ROS scavenging.
Fig. 3. FOXO-mediated cytoprotective enzymes scavenge ROS. FOXO regulates the
expressions of MnSOD (SOD2) and catalase (CAT). MnSOD convert superoxide into
H2O2, followed by the conversion into H2O and O2 by CAT.
Fig. 4. SIRT-mediated cytoprotective enzymes scavenge ROS. SIRT regulates the
expressions of MnSOD (SOD2) and catalase (CAT). MnSOD convert superoxide into
H2O2, followed by the conversion into H2O and O2 by CAT.
H. Kanzaki et al. / Redox Biology 8 (2016) 186–191188sirtuin) negatively regulates osteoclastogenesis via attenuation of
intracellular ROS signaling (Fig. 5).5. Regulatory mechanisms of potential pharmacological tar-
gets for bone destructive diseases
As discussed above, osteoclasts also possess mechanisms that
regulate cytoprotective enzymes, which manage the intracellular
ROS levels. Since intracellular ROS play a role in RANKL-mediated
osteoclastogenesis, the mechanisms that regulate cytoprotectiveenzymes negatively control osteoclastogenesis via ROS scavenging
mediated by cytoprotective enzymes. In other words, osteoclas-
togenesis is controlled via interference with the mechanisms
regulating cytoprotective enzymes.
Indeed, some papers report that the activation of Nrf2 inhibits
osteoclastogenesis [6,73,74]. The pharmacological activation of
Nrf2 has been extensively explored in cancer research and che-
mical detoxiﬁcation ﬁelds, thus potential Nrf2 activators such as
sulforaphane [78], epigallocatechin gallate [79], curcumin [80],
and N-acetylcysteine [81] are well-documented and known to
inhibit bone destruction [72,82–84]. Another regulatory molecule,
FOXO, is also a potential therapeutic target for bone destructive
diseases. Statins, HMG-CoA reductase inhibitors, induce FOXO
phosphorylation [85] and exhibit osteoclastogenesis by ROS
scavenging [86]. Regarding sirtuin-mediated regulatory mechan-
isms, resveratrol, an agonist of SIRT1 [87], inhibits osteoclasto-
genesis through the attenuation of ROS production [88–90]. In-
deed, sirtuin activators such as resveratrol or other synthesized
chemicals inhibit bone destruction [91–94]. Some of the chemicals
reported to activate cytoprotective enzymes and thereby inhibit
bone destruction are summarized in Table 2.6. Summary and perspective
In this review manuscript, we have summarized recent in-
formation about the relationship between osteoclastogenesis and
the mechanisms regulating cytoprotective enzymes. Although
some parts have been extensively explored, further investigations
Fig. 5. Nrf2, FOXO, and sirtuin negatively regulate osteoclastogenesis via attenua-
tion of intracellular ROS signaling. Nrf2 regulates the transcription of cytoprotective
enzymes and ROS scavenging. However, Keap1 attenuates cytoprotective enzymes
via degradation of Nrf2. Other mechanisms regulating cytoprotective enzymes have
roles in ROS regulation: FOXO directly, and sirtuin directly and indirectly (via
FOXO).
Table 2
Reported chemicals that can activate
















H. Kanzaki et al. / Redox Biology 8 (2016) 186–191 189are necessary to gain a greater understanding. In particular,
crosstalk among the mechanisms regulating cytoprotective en-
zymes and other signaling molecules should be elucidated.
Since some of the agonists that affect the mechanisms reg-
ulating cytoprotective enzymes have been reported as inhibitors of
bone destruction, these chemicals could be potential drugs for the
treatment for bone destructive diseases in the near future.Acknowledgments
This research was supported by Grants-in-Aid for Scientiﬁc
Research from the Japan Society for the Promotion of Science
(23689081, 25670841, and 15K11376), the Nestle Nutrition Coun-
cil, Japan, the Translational Research Network Program from the
Japanese Ministry of Education, Culture, Sports, Science andTechnology (A-03), the Adaptable and Seamless Technology
Transfer Program through Target-driven R&D from the Japan Sci-
ence and Technology Agency (AS231Z01205G), and the Astellas
Foundation for Research on Metabolic Disorders. The authors have
no conﬂicts of interest.
Finally, the authors (HK and FS) give their heartfelt apprecia-
tion to the experimental reagent and instrument companies for
their support during the rehabilitation process following the da-
mage caused by the Tohoku Earthquake on March 11, 2011.References
[1] G.D. Roodman, Advances in bone biology: the osteoclast, Endocr. Rev. 17
(1996) 308–332.
[2] S.L. Teitelbaum, M.M. Tondravi, F.P. Ross, Osteoclasts, macrophages, and the
molecular mechanisms of bone resorption, J. Leukoc. Biol. 61 (1997)
381–388.
[3] D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott,
A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy,
C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi,
J. Guo, J. Delaney, W.J. Boyle, Osteoprotegerin ligand is a cytokine that reg-
ulates osteoclast differentiation and activation, Cell 93 (1998) 165–176.
[4] B.E. Bax, A.S. Alam, B. Banerji, C.M. Bax, P.J. Bevis, C.R. Stevens, B.S. Moonga, D.
R. Blake, M. Zaidi, Stimulation of osteoclastic bone resorption by hydrogen
peroxide, Biochem. Biophys. Res. Commun. 183 (1992) 1153–1158.
[5] H. Ha, H.B. Kwak, S.W. Lee, H.M. Jin, H.M. Kim, H.H. Kim, Z.H. Lee, Reactive
oxygen species mediate RANK signaling in osteoclasts, Exp. Cell Res. 301
(2004) 119–127.
[6] H. Kanzaki, F. Shinohara, M. Kajiya, S. Fukaya, Y. Miyamoto, Y. Nakamura,
Nuclear nrf2 induction by protein transduction attenuates osteoclastogenesis,
Free Radic. Biol. Med. 77 (2014) 239–248.
[7] H. Esterbauer, R.J. Schaur, H. Zollner, Chemistry and biochemistry of 4-hy-
droxynonenal, malonaldehyde and related aldehydes, Free Radic. Biol. Med. 11
(1991) 81–128.
[8] P.G. Wells, G.P. McCallum, C.S. Chen, J.T. Henderson, C.J.J. Lee, J. Perstin, T.
J. Preston, M.J. Wiley, A.W. Wong, Oxidative stress in developmental origins of
disease: teratogenesis, neurodevelopmental deﬁcits, and cancer, Toxicol. Sci.
108 (2009) 4–18.
[9] T.W. Kensler, N. Wakabayashi, S. Biswal, Cell survival responses to environ-
mental stresses via the Keap1-Nrf2-ARE pathway, Annu. Rev. Pharmacol.
Toxicol. 47 (2007) 89–116.
[10] Y. Furukawa-Hibi, Y. Kobayashi, C. Chen, N. Motoyama, FOXO transcription
factors in cell-cycle regulation and the response to oxidative stress, Antioxid.
Redox Signal 7 (2005) 752–760.
[11] C.P. Hsu, I. Odewale, R.R. Alcendor, J. Sadoshima, Sirt1 protects the heart from
aging and stress, Biol. Chem. 389 (2008) 221–231.
[12] J.M. Mates, F. Sanchez-Jimenez, Antioxidant enzymes and their implications in
pathophysiologic processes, Front. Biosci. 4 (1999) D339–D345.
[13] J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, Cook J.L. Nrf2, a
Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1
gene, J. Biol. Chem. 274 (1999) 26071–26078.
[14] L.V. Favreau, C.B. Pickett, Transcriptional regulation of the rat NAD(P)H:qui-
none reductase gene. Identiﬁcation of regulatory elements controlling basal
level expression and inducible expression by planar aromatic compounds and
phenolic antioxidants, J. Biol. Chem. 266 (1991) 4556–4561.
[15] A.C. Wild, J.J. Gipp, T. Mulcahy, Overlapping antioxidant response element and
PMA response element sequences mediate basal and beta-naphthoﬂavone-
induced expression of the human gamma-glutamylcysteine synthetase cata-
lytic subunit gene, Biochem. J. 332 (2) (1998) 373–381.
[16] R.K. Thimmulappa, K.H. Mai, S. Srisuma, T.W. Kensler, M. Yamamoto, S. Biswal,
Identiﬁcation of Nrf2-regulated genes induced by the chemopreventive agent
sulforaphane by oligonucleotide microarray, Cancer Res. 62 (2002) 5196–5203.
[17] S. Zhang, C. Song, J. Zhou, L. Xie, X. Meng, P. Liu, J. Cao, X. Zhang, W.Q. Ding,
J. Wu, Amelioration of radiation-induced skin injury by adenovirus-mediated
heme oxygenase-1 (HO-1) overexpression in rats, Radiat. Oncol. 7 (2012) 4.
[18] R. Pazdro, J.R. Burgess, The antioxidant 3H-1,2-dithiole-3-thione potentiates
advanced glycation end-product-induced oxidative stress in SH-SY5Y cells,
Exp. Diabetes Res. 2012 (2012) 137607.
[19] S. Akazawa, Diabetic embryopathy: studies using a rat embryo culture system
and an animal model, Congenit. Anom. 45 (2005) 73–79.
[20] H. Gurer-Orhan, H. Orhan, S. Suzen, M.O. Puskullu, E. Buyukbingol, Synthesis
and evaluation of in vitro antioxidant capacities of some benzimidazole de-
rivatives, J. Enzyme Inhib. Med. Chem. 21 (2006) 241–247.
[21] B.R. Wong, J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov,
E. Cayani, F.S. Bartlett 3rd, W.N. Frankel, S.Y. Lee, Y. Choi, TRANCE is a novel
ligand of the tumor necrosis factor receptor family that activates c-Jun
N-terminal kinase in T cells, J. Biol. Chem. 272 (1997) 25190–25194.
[22] H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki,
A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga,
K. Higashio, N. Udagawa, N. Takahashi, T. Suda, Osteoclast differentiation
factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and
H. Kanzaki et al. / Redox Biology 8 (2016) 186–191190is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. U.S.A. 95 (1998)
3597–3602.
[23] K. Fuller, B. Wong, S. Fox, Y. Choi, T.J. Chambers, TRANCE is necessary and
sufﬁcient for osteoblast-mediated activation of bone resorption in osteoclasts,
J. Exp. Med. 188 (1998) 997–1001.
[24] H. Hirotani, N.A. Tuohy, J.T. Woo, P.H. Stern, N.A. Clipstone, The calcineurin/
nuclear factor of activated T cells signaling pathway regulates osteoclasto-
genesis in RAW264.7 cells, J. Biol. Chem. 279 (2004) 13984–13992.
[25] T. Miyazaki, H. Katagiri, Y. Kanegae, H. Takayanagi, Y. Sawada, A. Yamamoto, M.
P. Pando, T. Asano, I.M. Verma, H. Oda, K. Nakamura, S. Tanaka, Reciprocal role
of ERK and NF-kappaB pathways in survival and activation of osteoclasts, J.
Cell Biol. 148 (2000) 333–342.
[26] S.E. Lee, K.M. Woo, S.Y. Kim, H.M. Kim, K. Kwack, Z.H. Lee, H.H. Kim, The
phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase
pathways are involved in osteoclast differentiation, Bone 30 (2002) 71–77.
[27] B.R. Wong, R. Josien, S.Y. Lee, M. Vologodskaia, R.M. Steinman, Y. Choi, The
TRAF family of signal transducers mediates NF-kappaB activation by the
TRANCE receptor, J. Biol. Chem. 273 (1998) 28355–28359.
[28] B.G. Darnay, V. Haridas, J. Ni, P.A. Moore, B.B. Aggarwal, Characterization of the
intracellular domain of receptor activator of NF-kappaB (RANK). Interaction
with tumor necrosis factor receptor-associated factors and activation
of NF-kappab and c-Jun N-terminal kinase, J. Biol. Chem. 273 (1998)
20551–20555.
[29] H.H. Kim, D.E. Lee, J.N. Shin, Y.S. Lee, Y.M. Jeon, C.H. Chung, J. Ni, B.S. Kwon, Z.
H. Lee, Receptor activator of NF-kappaB recruits multiple TRAF family adaptors
and activates c-Jun N-terminal kinase, FEBS Lett. 443 (1999) 297–302.
[30] B.R. Wong, D. Besser, N. Kim, J.R. Arron, M. Vologodskaia, H. Hanafusa, Y. Choi,
TRANCE, a TNF family member, activates Akt/PKB through a signaling complex
involving TRAF6 and c-Src, Mol. Cell 4 (1999) 1041–1049.
[31] F. Wauquier, L. Leotoing, V. Coxam, J. Guicheux, Y. Wittrant, Oxidative stress in
bone remodelling and disease, Trends Mol. Med. 15 (2009) 468–477.
[32] O. Altindag, O. Erel, N. Soran, H. Celik, S. Selek, Total oxidative/anti-oxidative
status and relation to bone mineral density in osteoporosis, Rheumatol. Int. 28
(2008) 317–321.
[33] M. Almeida, L. Han, M. Martin-Millan, L.I. Plotkin, S.A. Stewart, P.K. Roberson,
S. Kousteni, C.A. O'Brien, T. Bellido, A.M. Parﬁtt, R.S. Weinstein, R.L. Jilka, S.
C. Manolagas, Skeletal involution by age-associated oxidative stress and its
acceleration by loss of sex steroids, J. Biol. Chem. 282 (2007) 27285–27297.
[34] S. Muthusami, I. Ramachandran, B. Muthusamy, G. Vasudevan, V. Prabhu,
V. Subramaniam, A. Jagadeesan, S. Narasimhan, Ovariectomy induces oxidative
stress and impairs bone antioxidant system in adult rats, Clin. Chim. Acta 360
(2005) 81–86.
[35] I.R. Garrett, B.F. Boyce, R.O. Oreffo, L. Bonewald, J. Poser, G.R. Mundy, Oxygen-
derived free radicals stimulate osteoclastic bone resorption in rodent bone in
vitro and in vivo, J. Clin. Invest. 85 (1990) 632–639.
[36] S. Yalin, S. Bagis, G. Polat, N. Dogruer, S. Cenk Aksit, R. Hatungil, C. Erdogan, Is
there a role of free oxygen radicals in primary male osteoporosis? Clin. Exp.
Rheumatol. 23 (2005) 689–692.
[37] D. Harman, Aging: a theory based on free radical and radiation chemistry, J.
Gerontol. 11 (1956) 298–300.
[38] N. Suda, I. Morita, T. Kuroda, S. Murota, Participation of oxidative stress in the
process of osteoclast differentiation, Biochim. Biophys. Acta 1157 (1993)
318–323.
[39] N.K. Lee, Y.G. Choi, J.Y. Baik, S.Y. Han, D.W. Jeong, Y.S. Bae, N. Kim, S.Y. Lee, A
crucial role for reactive oxygen species in RANKL-induced osteoclast differ-
entiation, Blood 106 (2005) 852–859.
[40] A. Abo, E. Pick, A. Hall, N. Totty, C.G. Teahan, A.W. Segal, Activation of the
NADPH oxidase involves the small GTP-binding protein p21rac1, Nature 353
(1991) 668–670.
[41] Y. Wang, D. Lebowitz, C. Sun, H. Thang, M.D. Grynpas, M. Glogauer, Identifying
the relative contributions of Rac1 and Rac2 to osteoclastogenesis, J. Bone
Miner. Res. 23 (2008) 260–270.
[42] H. Sasaki, H. Yamamoto, K. Tominaga, K. Masuda, T. Kawai, S. Teshima-Kondo,
K. Matsuno, C. Yabe-Nishimura, K. Rokutan, Receptor activator of nuclear
factor-kappaB ligand-induced mouse osteoclast differentiation is associated
with switching between NADPH oxidase homologues, Free Radic. Biol. Med.
47 (2009) 189–199.
[43] H. Sasaki, H. Yamamoto, K. Tominaga, K. Masuda, T. Kawai, S. Teshima-Kondo,
K. Rokutan, NADPH oxidase-derived reactive oxygen species are essential for
differentiation of a mouse macrophage cell line (RAW264.7) into osteoclasts, J.
Med. Invest. 56 (2009) 33–41.
[44] D.A. Callaway, J.X. Jiang, Reactive oxygen species and oxidative stress in os-
teoclastogenesis, skeletal aging and bone diseases, J. Bone Miner. Metab. 33
(2015) 359–370.
[45] V.J. Thannickal, B.L. Fanburg, Reactive oxygen species in cell signaling, Am. J.
Physiol. Lung Cell Mol. Physiol. 279 (2000) L1005–L1028.
[46] W. Droge, Free radicals in the physiological control of cell function, Physiol.
Rev. 82 (2002) 47–95.
[47] A.C. Bharti, Y. Takada, B.B. Aggarwal, Curcumin (diferuloylmethane) inhibits
receptor activator of NF-kappa B ligand-induced NF-kappa B activation in
osteoclast precursors and suppresses osteoclastogenesis, J. Immunol. 172
(2004) 5940–5947.
[48] K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, M. Yamamoto,
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2
through binding to the amino-terminal Neh2 domain, Genes Dev. 13 (1999)
76–86.[49] J.W. Liu, D. Chandra, M.D. Rudd, A.P. Butler, V. Pallotta, D. Brown, P.J. Coffer, D.
G. Tang, Induction of prosurvival molecules by apoptotic stimuli: involvement
of FOXO3a and ROS, Oncogene 24 (2005) 2020–2031.
[50] M.K. Lehtinen, Z. Yuan, P.R. Boag, Y. Yang, J. Villen, E.B. Becker, S. DiBacco, N. de
la Iglesia, S. Gygi, T.K. Blackwell, A. Bonni, A conserved MST-FOXO signaling
pathway mediates oxidative-stress responses and extends life span, Cell 125
(2006) 987–1001.
[51] S. Nemoto, T. Finkel, Redox regulation of forkhead proteins through a p66shc-
dependent signaling pathway, Science 295 (2002) 2450–2452.
[52] S. Murakami, Stress resistance in long-lived mouse models, Exp. Gerontol. 41
(2006) 1014–1019.
[53] M.E. Giannakou, L. Partridge, The interaction between FOXO and SIRT1: tip-
ping the balance towards survival, Trends Cell Biol. 14 (2004) 408–412.
[54] G.J. Kops, T.B. Dansen, P.E. Polderman, I. Saarloos, K.W.Wirtz, P.J. Coffer, T.T. Huang,
J.L. Bos, R.H. Medema, B.M. Burgering, Forkhead transcription factor FOXO3a
protects quiescent cells from oxidative stress, Nature 419 (2002) 316–321.
[55] M.A. Essers, S. Weijzen, A.M. de Vries-Smits, I. Saarloos, N.D. de Ruiter, J.L. Bos,
B.M. Burgering, FOXO transcription factor activation by oxidative stress
mediated by the small GTPase Ral and JNK, EMBO J. 23 (2004) 4802–4812.
[56] R.L. Baehner, S.K. Murrmann, J. Davis, R.B. Johnston Jr., The role of superoxide
anion and hydrogen peroxide in phagocytosis-associated oxidative metabolic
reactions, J. Clin. Invest. 56 (1975) 571–576.
[57] O.A. Loew, New enzyme of general occurrence in organisms, Science 11 (1900)
701–702.
[58] S.C. Grace, Phylogenetic distribution of superoxide dismutase supports an
endosymbiotic origin for chloroplasts and mitochondria, Life Sci. 47 (1990)
1875–1886.
[59] S.G. Gray, T.J. Ekstrom, The human histone deacetylase family, Exp. Cell Res.
262 (2001) 75–83.
[60] Y. Chen, J. Zhang, Y. Lin, Q. Lei, K.L. Guan, S. Zhao, Y. Xiong, Tumour suppressor
SIRT3 deacetylates and activates manganese superoxide dismutase to sca-
venge ROS, EMBO Rep. 12 (2011) 534–541.
[61] O. Ozden, S.H. Park, H.S. Kim, H. Jiang, M.C. Coleman, D.R. Spitz, D. Gius,
Acetylation of MnSOD directs enzymatic activity responding to cellular nu-
trient status or oxidative stress, Aging 3 (2011) 102–107.
[62] K. Hasegawa, S. Wakino, K. Yoshioka, S. Tatematsu, Y. Hara, H. Minakuchi,
N. Washida, H. Tokuyama, K. Hayashi, H. Itoh, Sirt1 protects against oxidative
stress-induced renal tubular cell apoptosis by the bidirectional regulation of
catalase expression, Biochem. Biophys. Res. Commun. 372 (2008) 51–56.
[63] S. Michan, D. Sinclair, Sirtuins in mammals: insights into their biological
function, Biochem. J. 404 (2007) 1–13.
[64] A. van der Horst, L.G.J. Tertoolen, L.M.M. de Vries-Smits, R.A. Frye, R.
H. Medema, B.M.T. Burgering, FOXO4 Is Acetylated upon Peroxide Stress and
Deacetylated by the Longevity Protein hSir2SIRT1, J. Biol. Chem. 279 (2004)
28873–28879.
[65] Y. Olmos, F.J. Sanchez-Gomez, B. Wild, N. Garcia-Quintans, S. Cabezudo,
S. Lamas, M. Monsalve, SirT1 regulation of antioxidant genes is dependent on
the formation of a FoxO3a/PGC-1alpha complex, Antioxid. Redox Signal 19
(2013) 1507–1521.
[66] K. Huang, C. Chen, J. Hao, J. Huang, S. Wang, P. Liu, H. Huang, Polydatin pro-
motes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-
induced upregulation of ﬁbronetin and transforming growth factor-beta1 in rat
glomerular messangial cells, Mol. Cell Endocrinol. 399 (2015) 178–189.
[67] J. Zwerina, S. Tzima, S. Hayer, K. Redlich, O. Hoffmann, B. Hanslik-Schnabel, J.
S. Smolen, G. Kollias, G. Schett, Heme oxygenase 1 (HO-1) regulates osteo-
clastogenesis and bone resorption, FASEB J. 19 (2005) 2011–2013.
[68] E. Sakai, M. Shimada-Sugawara, K. Nishishita, Y. Fukuma, M. Naito,
K. Okamoto, K. Nakayama, T. Tsukuba, Suppression of RANKL-dependent heme
oxygenase-1 is required for high mobility group box 1 release and osteo-
clastogenesis, J. Cell Biochem. 113 (2012) 486–498.
[69] K. Ke, M.A. Safder, O.J. Sul, W.K. Kim, J.H. Suh, Y. Joe, H.T. Chung, H.S. Choi,
Hemeoxygenase-1 maintains bone mass via attenuating a redox imbalance in
osteoclast, Mol. Cell Endocrinol. 409 (2015) 11–20.
[70] T. Rana, M.A. Schultz, M.L. Freeman, S. Biswas, Loss of Nrf2 accelerates ionizing
radiation-induced bone loss by upregulating RANKL, Free Radic. Biol. Med. 53
(2012) 2298–2307.
[71] H. Kanzaki, F. Shinohara, M. Kajiya, T. Kodama, The Keap1/Nrf2 protein axis
plays a role in osteoclast differentiation by regulating intracellular reactive
oxygen species signaling, J. Biol. Chem. 288 (2013) 23009–23020.
[72] S. Hyeon, H. Lee, Y. Yang, W. Jeong, Nrf2 deﬁciency induces oxidative stress
and promotes RANKL-induced osteoclast differentiation, Free Radic. Biol. Med.
65 (2013) 789–799.
[73] L. Gambari, G. Lisignoli, L. Cattini, C. Manferdini, A. Facchini, F. Grassi, Sodium
hydrosulﬁde inhibits the differentiation of osteoclast progenitor cells via
NRF2-dependent mechanism, Pharmacol. Res. 87 (2014) 99–112.
[74] H. Kanzaki, F. Shinohara, K. Itohiya-Kasuya, M. Ishikawa, Y. Nakamura, Nrf2
activation attenuates both orthodontic tooth movement and relapse, J. Dent.
Res. 94 (2015) 787–794.
[75] S.M. Bartell, H.N. Kim, E. Ambrogini, L. Han, S. Iyer, S. Serra Ucer,
P. Rabinovitch, R.L. Jilka, R.S. Weinstein, H. Zhao, C.A. O'Brien, S.C. Manolagas,
M. Almeida, FoxO proteins restrain osteoclastogenesis and bone resorption by
attenuating H2O2 accumulation, Nat. Commun. 5 (2014) 3773.
[76] H.N. Kim, L. Han, S. Iyer, R. de Cabo, H. Zhao, C.A. O'Brien, S.C. Manolagas,
M. Almeida, Sirtuin1 suppresses osteoclastogenesis by deacetylating FoxOs,
Mol. Endocrinol. 29 (10) (2015) 1498–1509, http://dx.doi.org/10.1210/
me.2015-1133.
H. Kanzaki et al. / Redox Biology 8 (2016) 186–191 191[77] H.S. Lee, S.O. Ka, S.M. Lee, S.I. Lee, J.W. Park, B.H. Park, Overexpression of sir-
tuin 6 suppresses inﬂammatory responses and bone destruction in mice with
collagen-induced arthritis, Arthritis Rheum. 65 (2013) 1776–1785.
[78] A.N. Kong, R. Yu, V. Hebbar, C. Chen, E. Owuor, R. Hu, R. Ee, S. Mandlekar,
Signal transduction events elicited by cancer prevention compounds, Mutat.
Res. 480–481 (2001) 231–241.
[79] G. Shen, C. Xu, R. Hu, M.R. Jain, S. Nair, W. Lin, C.S. Yang, J.Y. Chan, A.N. Kong,
Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine
gene expression proﬁles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice,
Pharm. Res. 22 (2005) 1805–1820.
[80] E. Balogun, M. Hoque, P. Gong, E. Killeen, C.J. Green, R. Foresti, J. Alam,
R. Motterlini, Curcumin activates the haem oxygenase-1 gene via regulation of
Nrf2 and the antioxidant-responsive element, Biochem. J. 371 (2003)
887–895.
[81] K.R. Sekhar, D.R. Spitz, S. Harris, T.T. Nguyen, M.J. Meredith, J.T. Holt, D. Gius, L.
J. Marnett, M.L. Summar, M.L. Freeman, Redox-sensitive interaction between
KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-
glutamylcysteine synthetase, Free Radic. Biol. Med. 32 (2002) 650–662.
[82] A. Morinobu, W. Biao, S. Tanaka, M. Horiuchi, L. Jun, G. Tsuji, Y. Sakai,
M. Kurosaka, S. Kumagai, (-)-Epigallocatechin-3-gallate suppresses osteoclast
differentiation and ameliorates experimental arthritis in mice, Arthritis
Rheum 58 (2008) 2012–2018.
[83] D.L. French, J.M. Muir, C.E. Webber, The ovariectomized, mature rat model of
postmenopausal osteoporosis: an assessment of the bone sparing effects of
curcumin, Phytomedicine 15 (2008) 1069–1078.
[84] K.M. Sanders, M.A. Kotowicz, G.C. Nicholson, Potential role of the antioxidant
N-acetylcysteine in slowing bone resorption in early post-menopausal wo-
men: a pilot study, Transl. Res. 150 (2007) 215.
[85] C. Urbich, A. Knau, S. Fichtlscherer, D.H. Walter, T. Bruhl, M. Potente, W.
K. Hofmann, S. de Vos, A.M. Zeiher, S. Dimmeler, FOXO-dependent expression
of the proapoptotic protein Bim: pivotal role for apoptosis signaling in en-
dothelial progenitor cells, FASEB J. 19 (2005) 974–976.
[86] H.J. Moon, S.E. Kim, Y.P. Yun, Y.S. Hwang, J.B. Bang, J.H. Park, I.K. Kwon, Sim-
vastatin inhibits osteoclast differentiation by scavenging reactive oxygen
species, Exp. Mol. Med. 43 (2011) 605–612.[87] J.B. Pillai, M. Chen, S.B. Rajamohan, S. Samant, V.B. Pillai, M. Gupta, M.P. Gupta,
Activation of SIRT1, a class III histone deacetylase, contributes to fructose
feeding-mediated induction of the alpha-myosin heavy chain expression, Am.
J. Physiol. Heart Circ. Physiol. 294 (2008) H1388–H1397.
[88] P. Boissy, T.L. Andersen, B.M. Abdallah, M. Kassem, T. Plesner, J.M. Delaisse,
Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and
promotes osteoblast differentiation, Cancer Res. 65 (2005) 9943–9952.
[89] X. He, G. Andersson, U. Lindgren, Y. Li, Resveratrol prevents RANKL-induced
osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells
through inhibition of ROS production, Biochem. Biophys. Res. Commun. 401
(2010) 356–362.
[90] M. Shakibaei, C. Buhrmann, A. Mobasheri, Resveratrol-mediated SIRT-1 in-
teractions with p300 modulate receptor activator of NF-kappaB ligand
(RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in
bone-derived cells, J. Biol. Chem. 286 (2011) 11492–11505.
[91] C.Y. Lai, J.Y. Yang, S. Rayalam, M.A. Della-Fera, S. Ambati, R.D. Lewis, M.
W. Hamrick, D.L. Hartzell, C.A. Baile, Preventing bone loss and weight gain
with combinations of vitamin D and phytochemicals, J. Med. Food 14 (2011)
1352–1362.
[92] H. Artsi, E. Cohen-Kﬁr, I. Gurt, R. Shahar, A. Bajayo, N. Kalish, T.M. Bellido,
Y. Gabet, R. Dresner-Pollak, The Sirtuin1 activator SRT3025 down-regulates
sclerostin and rescues ovariectomy-induced bone loss and biomechanical
deterioration in female mice, Endocrinology 155 (2014) 3508–3515.
[93] I. Momken, L. Stevens, A. Bergouignan, D. Desplanches, F. Rudwill, I. Chery,
A. Zahariev, S. Zahn, T.P. Stein, J.L. Sebedio, E. Pujos-Guillot, M. Falempin,
C. Simon, V. Coxam, T. Andrianjaﬁniony, G. Gauquelin-Koch, F. Picquet,
S. Blanc, Resveratrol prevents the wasting disorders of mechanical unloading
by acting as a physical exercise mimetic in the rat, FASEB J. 25 (2011)
3646–3660.
[94] E.M. Mercken, S.J. Mitchell, A. Martin-Montalvo, R.K. Minor, M. Almeida, A.
P. Gomes, M. Scheibye-Knudsen, H.H. Palacios, J.J. Licata, Y. Zhang, K.G. Becker,
H. Khraiwesh, J.A. Gonzalez-Reyes, J.M. Villalba, J.A. Baur, P. Elliott,
C. Westphal, G.P. Vlasuk, J.L. Ellis, D.A. Sinclair, M. Bernier, R. de Cabo, SRT2104
extends survival of male mice on a standard diet and preserves bone and
muscle mass, Aging Cell 13 (2014) 787–796.
